Novel Aryltriazole Acyclic C-Azanucleosides as Anticancer Candidates - Aix-Marseille Université Access content directly
Journal Articles Organic & Biomolecular Chemistry Year : 2020

Novel Aryltriazole Acyclic C-Azanucleosides as Anticancer Candidates


Nucleoside analogues represent an important class of drug candidates. With the aim of searching for novel bioactive nucleosides, we developed an efficient synthetic way to construct a series of aryl 1,2,3-triazole acyclic C-azanucleosides via Huisgen 1,3-dipolar cycloaddition. The aryl 1,2,3-triazole motifs within these azanucleosides showed coplanar features, suggesting they could act as surrogates for large planar aromatic systems or nucleobases. Moreover, several aryltriazole acyclic C-azanucleosides bearing long alkyl chains exhibited potent antiproliferative activity against various cancer cell lines via induction of apoptosis. Most interestingly, the lead compound significantly down-regulated the key proteins involved in the heat shock response pathway, representing the first anticancer acyclic azanucleoside with such a mode of action. These novel aryl 1,2,3-triazole cyclic C-azanucleosides therefore serve as promising paradigms for further exploring anticancer drug candidates.
Fichier principal
Vignette du fichier
Revised Manuscript.pdf (733.43 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-03041312 , version 1 (04-12-2020)



Yanhua Zhang, Yun Lin, Qianqian Hou, Xi Liu, Sabrina Pricl, et al.. Novel Aryltriazole Acyclic C-Azanucleosides as Anticancer Candidates. Organic & Biomolecular Chemistry, 2020, ⟨10.1039/d0ob02164d⟩. ⟨hal-03041312⟩
46 View
148 Download



Gmail Facebook X LinkedIn More